Document is current
Any future updates will be listed below
-
Authors
Stern, Sydney https://orcid.org/0000-0002-1479-605X
McKenzie, Patrick F.
Baldi, Giacomo G.
Scharschmidt, Thomas J.
Palmerini, Emanuela
Rothschild, Sara
- License Information
-
More Information
Article History
Received: 17 August 2025
Accepted: 21 January 2026
First Online: 30 January 2026
Declarations
:
: This analysis was approved by an institutional review board, Advarra (Columbia, Maryland) and the approved protocol reference number is Pro00077310. Written informed consent was obtained from each patient who participated in the registry.
: Patients provided written consent to the collection and analysis of their information. No data from individual patients is shown.
: Sydney Stern, Patrick McKenzie, and Sara Rothschild have no conflicts of interest to declare. Emanuela Palmerini has served on advisory boards for Daiichi Sankyo, Inc., Deciphera, EUSA Pharma, and SynOx Therapeutics. Giacomo Giulio Baldi, outside the submitted work: advisory role for Pharmamar, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dome, Deciphera. Consulting fees: Eli Lilly, Pharmamar. Honoraria: Pharmamar, Eli Lilly, Glaxo Smith Kline, Merck Sharp & Dome, IstitutoGentili. Travel grants: Istituto Gentili, Pharmamar, Eli Lilly. Thomas Scharschmidt has served as a consultant for Stryker, Onkos, AmMax Bio, Daichii Sankyo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
